JPRN-UMIN000012048
Completed
Phase 2
Phase II study of low-dose Nab-paclitaxel for advanced breast cancer - Phase II study of low-dose Nab-paclitaxel for advanced breast cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kitasato University Kitasato Institute Hospital
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) History of hypersensitivity reaction 2\) Active double cancer 3\) Other severe complications, such as uncontrolled diabetes mellitus, uncontrolled angina, myocardial infarction within 6 months, heart failure. 4\) Severe mental disorder 5\) Sever bone marrow suppression, renal dysfunction, liver dysfunction 6\) Has watery diarrhea 7\) Active infection or potentiality infection 8\) History of hypersensitivity for albumin 9\) Grade2 or grater peripheral neuropathy 10\) Pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant 11\) Judged ineligible based on physicians' decision
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
A phase II study of low dose nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancerunresectable or recurrent gastric canceJPRN-UMIN000016196Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine37
Recruiting
Phase 2
Phase 2 study of dose-dense nab-paclitaxel followed by EC as neoadjuvant chemotherapy for HER2-negative breast cancerHER2-negative primary breast cancerJPRN-UMIN000026143Teikyo University School of Medicine50
Completed
Not Applicable
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30
Completed
Phase 2
A phase 2 trial of weekly nab-paclitaxel for advanced non-small cell lung cancer without EGFR mutation nor ALK fusion gene in salvage settingJPRN-UMIN000016173Kurashiki Central Hospital38
Completed
Phase 2
Phase II clinical study of nab-paclitaxel for patients with recurrent advanced non-small cell lung cancer.advanced non-small cell lung cancerJPRN-UMIN000016932The Japan-Multinational Trial Organization (JMTO)81